Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Non-small Cell Lung Cancer
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Patient received durvalumab monotherapy and/or durvalumab containing combination in an AstraZeneca/MedImmune-sponsored parent clinical study that is approved for enrollment into this study. 2) Patient who received durvalumab in combination with any other approved or investigational anticancer agents in the parent clinical study must have completed or discontinued all other anticancer therapy (beyond durvalumab regimen).
  

You may not be eligible for this study if the following are true:

• 1) Currently receiving treatment in another interventional clinical study other than a parent clinical study, or received treatment during the follow -up period before retreatment. 2) Experienced an immune-mediated or non-immune-mediated (hematologic and non-hematologic) toxicity that led to permanent discontinuation of durvalumab in the parent clinical study.